The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

Shiraz University of Medical Sciences42 enrolled

Overview

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hyperphosphatemia

Interventions

Mg OxideDRUG

250 mg orally for 4 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: hemodialysis with duration\>3 months serum P level \>5.5 mg/dl serum Ca\>8 mg/dl. Exclusion Criteria: Mg level \>3 mg/dl

Locations (1)

Shiraz University Hemodialysis Center

Shiraz, Fars, Iran

Outcomes

Primary Outcomes

plasma phosphate level

Time frame: 4 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.